✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

CARsgen Therapeutics Holdings Ltd

Common Name
CARsgen Therapeutics Holdings
Country
China (Mainland)
Sector
Healthcare
Industry
Biotechnology
Employees
371
Ticker
2171
Exchange
HONG KONG EXCHANGES AND CLEARING LTD
Description
Carsgen Therapeutics Holdings Limited is a biopharmaceutical company that focuses on innovative CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment. The company's primary aim is to...

CARsgen Therapeutics Holdings's GHG Emissions Data Preview

In 2023, CARsgen Therapeutics Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, CARsgen Therapeutics Holdings has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202320222021
2020 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Unspecified Calculation Method
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of CARsgen Therapeutics Holdings’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2021, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=2171&reporting_period=2024"

Verified Sources Behind CARsgen Therapeutics Holdings’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CARsgen Therapeutics Holdings’s data sources below and access millions more through our Disclosure Search.

a. CARsgen Therapeutics Holdings's Annual Report 2023

Insights into CARsgen Therapeutics Holdings's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of CARsgen Therapeutics Holdings amounted to 15,327.77 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2022, the total operational greenhouse gas (GHG) emissions of CARsgen Therapeutics Holdings decreased by 10.78%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

CARsgen Therapeutics Holdings's Scope 1 Emissions Over Time

20212022202301.5 k3 k4.5 k6 ktCO2e+4197%-28%
  • Total Scope 1
  • Year-over-Year Change

What are CARsgen Therapeutics Holdings's Scope 1 emissions?

In 2023, the total Scope 1 emissions of CARsgen Therapeutics Holdings were 3,639.12 metric tons of CO₂ equivalent (tCO₂e).a

Has CARsgen Therapeutics Holdings reduced its Scope 1 emissions over time?

Since 2021, CARsgen Therapeutics Holdings's Scope 1 emissions have increased by 3,007.7%, reflecting a rising long-term trend in Scope 1 emissions over time.a

Compared to the previous year (2022), CARsgen Therapeutics Holdings's Scope 1 emissions decreased by 27.68%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are CARsgen Therapeutics Holdings's Scope 2 emissions?

In 2023, CARsgen Therapeutics Holdings reported Scope 2 greenhouse gas (GHG) emissions of 11,688.65 tCO₂e without specifying the calculation method.a

Has CARsgen Therapeutics Holdings reduced its Scope 2 emissions over time?

Since 2021, CARsgen Therapeutics Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 26.11%, reflecting a rising long-term trend in Scope 2 emissions over time.a

Compared to the previous year (2022), CARsgen Therapeutics Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CARsgen Therapeutics Holdings's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does CARsgen Therapeutics Holdings use for Scope 2 reporting?

In 2023, CARsgen Therapeutics Holdings reported its Scope 2 emissions using an unspecified methodology.a

CARsgen Therapeutics Holdings's Scope 2 Emissions Over Time

20212022202303.5 k7 k10.5 k14 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into CARsgen Therapeutics Holdings’s GHG Emissions Intensity Compared to Industry Peers

In 2021, CARsgen Therapeutics Holdings reported Scope 1 greenhouse gas (GHG) emissions of 117.1 tCO₂e and total revenues of USD 4 millions. This translates into an emissions intensity of 28.91 tCO₂e per millions USD.a

CARsgen Therapeutics Holdings's Scope 1 Emissions Intensity Compared to Peers

0.5102005,000100,000Scope 1 Emissions (tCO2e)2202001,00010,000Revenues (Millions of USD)AASDAntengeneYear: 2023Scope 1: 45 tCO2eRevenue: $M 10Scope 1 Intensity: 4.37 tCO2e/$MShanghai Henlius BiotechYear: 2023Scope 1: 6,909 tCO2eRevenue: $M 830Scope 1 Intensity: 8.32 tCO2e/$MRemeGenYear: 2024Scope 1: 54 tCO2eRevenue: $M 234Scope 1 Intensity: 0.23 tCO2e/$MGenscript BiotechYear: 2024Scope 1: 39,377 tCO2eRevenue: $M 4,637Scope 1 Intensity: 8.49 tCO2e/$MAAAscentage PharmaYear: 2023Scope 1: 2,081 tCO2eRevenue: $M 34Scope 1 Intensity: 61.05 tCO2e/$MShanghai Junshi BiosciencesYear: 2024Scope 1: 5,308 tCO2eRevenue: $M 267Scope 1 Intensity: 19.88 tCO2e/$MEverest MedicinesYear: 2024Scope 1: 1 tCO2eRevenue: $M 106Scope 1 Intensity: 0.00 tCO2e/$MInnovent BiologicsYear: 2024Scope 1: 48 tCO2eRevenue: $M 1,409Scope 1 Intensity: 0.03 tCO2e/$MAkesoYear: 2024Scope 1: 6,408 tCO2eRevenue: $M 318Scope 1 Intensity: 20.17 tCO2e/$MAAAurisco PharmaceuticalYear: 2024Scope 1: 2,731 tCO2eRevenue: $M 202Scope 1 Intensity: 13.51 tCO2e/$MZai LabYear: 2023Scope 1: 15 tCO2eRevenue: $M 267Scope 1 Intensity: 0.06 tCO2e/$MSSSichuan Kelun-Biotech BiopharmaceuticalYear: 2023Scope 1: 6,335 tCO2eRevenue: $M 237Scope 1 Intensity: 26.78 tCO2e/$MDDDaShenLin Pharmaceutical GroupYear: 2024Scope 1: 5,220 tCO2eRevenue: $M 3,631Scope 1 Intensity: 1.44 tCO2e/$MZhifeiYear: 2024Scope 1: 13,576 tCO2eRevenue: $M 3,572Scope 1 Intensity: 3.80 tCO2e/$MKintor PharmaceuticalYear: 2021Scope 1: 29 tCO2eRevenue: $M 5Scope 1 Intensity: 5.35 tCO2e/$MAscletis PharmaYear: 2023Scope 1: 422 tCO2eRevenue: $M 9Scope 1 Intensity: 48.50 tCO2e/$M3SBioYear: 2024Scope 1: 13,304 tCO2eRevenue: $M 1,364Scope 1 Intensity: 9.75 tCO2e/$MVIVA Biotech HoldingsYear: 2022Scope 1: 1,404 tCO2eRevenue: $M 373Scope 1 Intensity: 3.76 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MJacobio Pharmaceuticals GroupYear: 2023Scope 1: 34 tCO2eRevenue: $M 10Scope 1 Intensity: 3.48 tCO2e/$MAsymchem Laboratories (Tianjin)Year: 2024Scope 1: 31,787 tCO2eRevenue: $M 795Scope 1 Intensity: 39.96 tCO2e/$MWuXi Biologics (Cayman)Year: 2024Scope 1: 38,346 tCO2eRevenue: $M 2,779Scope 1 Intensity: 13.80 tCO2e/$MAlphamab OncologyYear: 2023Scope 1: 3,970 tCO2eRevenue: $M 34Scope 1 Intensity: 117.90 tCO2e/$MCARsgen Therapeutics HoldingsYear: 2021Scope 1: 117 tCO2eRevenue: $M 4Scope 1 Intensity: 28.91 tCO2e/$M

How does CARsgen Therapeutics Holdings's GHG emissions intensity compare to its peers?

In 2021, CARsgen Therapeutics Holdings reported a Scope 1 emissions intensity of 28.91 tCO₂e per millions USD. Compared to the peer group median of 8.49, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does CARsgen Therapeutics Holdings rank on GHG emissions intensity within its industry?

In 2021, CARsgen Therapeutics Holdings ranked 20 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places CARsgen Therapeutics Holdings among the least efficient performers, with one of the highest emissions intensities in its sector.a

Want Full Access to CARsgen Therapeutics Holdings's GHG Emissions Dataset?
Start 30-Day Free Trial